Familial Hypercholesterolaemia (FH) is a congenital disorder of lipid metabolism, which is characterized by a marked increase of LDL cholesterol in blood plasma from childhood and by early manifestation of coronary heart disease (CHD). The FH is autosomal dominant inherited and is the most common monogenic inherited disease with an estimated prevalence of 1:250. Early diagnosis and therapy can reduce the risk of atherosclerosis and its comorbidities to the level of the general population, especially in heterozygous patients. In Germany, as in most European countries, there is currently no corresponding early detection screening program.
The Vroni study intends to offer all children in the Free State of Bavaria a screening test as part of the preliminary examinations U9 to J1 (5-14 years), or as part of any other visit to a pediatrician.
Managed by BioM Biotech Cluster Development GmbH
Copyright © 2019 BioM Biotech Cluster Development GmbH
Alle Rechte vorbehalten